Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials
<p>Abstract</p> <p>Background</p> <p>Response rate (RR), the most common early means of assessing oncology drugs, is not suitable as the sole endpoint for phase II trials of drugs which induce disease stability but not regression. Time to progression (TTP) may be more s...
Main Authors: | Goffin John R, Pond Greg R |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-12-01
|
Series: | BMC Medical Research Methodology |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1471-2288/11/164 |
Similar Items
-
The Business Judgment Rule in a Progressive Legal Perspective: Essence and Implications in Indonesia
by: Wilda Shafira, et al.
Published: (2022-12-01) -
The Reconstruction of the Implementation from Business Judgment Rule Doctrine in Individual Limited Liability Companies: A Progressive Legal Review
by: Lisma Lumentut, et al.
Published: (2023-10-01) -
Optimal futility stopping boundaries for binary endpoints
by: Michaela Maria Freitag, et al.
Published: (2024-03-01) -
Tracking tumor heterogeneity and progression with near‐infrared II fluorophores
by: Qi Xin, et al.
Published: (2023-04-01) -
On deciding when to stop metaheuristics: Properties, rules and termination conditions
by: Albert Corominas
Published: (2023-01-01)